White Paper: Why BACS Clinical Trial Payments Will Fail MHRA Inspection

1. Introduction: The Audit Clif is coming

Q: Is BACS compliant for UK clinical trial participant reimbursement in 2026?

A: While BACS is a valid payment method, using it alongside manual spreadsheets fails the 2026 MHRA audit standards. These legacy processes lack the Contemporaneous and Attributable data integrity required by the new Regulation 31A and updated GCP guidelines.

The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025, coming into force on 28 April 2026, represent the most significant reform of UK clinical trial regulation in over two decades^[1]. Together with the updated ICH E6(R3) Good Clinical Practice (GCP) guidelines, these changes significantly raise the bar for how BACS participant payments and other financial records in UK clinical trials are documented and evidenced during an MHRA inspection.

Sponsors and CROs now need to demonstrate ALCOA+ data integrity not just for clinical data, but also for BACS clinical trial payments and reimbursement workflows.

For the first time, the MHRA will have the power to issue infringement notices for incomplete or unattributable data trails. Financial records, including participant expense reimbursements, are no longer exempt. Yet across the UK, hundreds of trials are still processing participant payments via manual BACS transfers, spreadsheets, and email.

This is the "BACS Governance Trap": a dangerous disconnect between the clinical record and the financial record that will not survive an inspection under the new framework. This paper sets out exactly why manual BACS processes are no longer fit for purpose, and what organisations must do before April 2026 to avoid falling off the audit cliff

2. Why BACS participant payments will fail a 2026 MHRA audit

Q: Why do manual BACS payments fail MHRA data integrity audits?

A: Manual BACS processes fail the ALCOA+ standard because they are not Contemporaneous (recorded at the time of the event) or Attributable (clearly linked to an authorised user). The 4-12 week lag common in BACS workflows creates a data gap that prevents auditors from accurately reconstructing the trial's financial history.

The April 2026 legislation fundamentally changes the compliance landscape for organisations still processing payments via BACS. Here is how legacy systems fail the new test:

2.1 Inspection Readiness - The New Data Standard

The updated GCP guidance mandates that all trial data must meet the ALCOA+ standard: Attributable, Legible, Contemporaneous, Original, and Accurate. Manual BACS workflows fail on three fronts:

Attributable: Fragmented systems and shadow Excel trackers make it difficult to confirm who authorised each transaction or trace a payment’s full lifecycle from visit to bank clearance. Without a single, reliable audit trail, routine payments become a compliance risk.

Contemporaneous: BACS payments are often processed in batches, sometimes weeks after a participant’s visit. This delay breaks the link between the clinical event and the financial record, directly conflicting with the requirement to record data at the time of the activity.

Accurate: Manual data entry consistently introduces errors. Across hundreds of participants and multiple visits, even a small error rate quickly compounds. To an auditor, patterns of missing attribution, inconsistent timestamps, and avoidable input mistakes raise questions about the reliability of the wider trial record..

2.2 Audit Trails That Last: The 25-Year Rule

Starting 28 April 2026, the mandatory archiving period for clinical trial records increases from 5 to 25 years^[2]. Critically, this does not just cover medical data; under updated ICH E6(R3) guidelines, it includes every piece of metadata and financial evidence related to participant payments^[3]. What feels like a routine reimbursement today carries a quarter-century of storage and security obligations.

For organisations still relying on paper files, email folders, or shared drives, this is not a minor administrative inconvenience; it is significant regulatory exposure. Paper deteriorates, inboxes get deleted when people leave, share drives get moved around and files get accidentally deleted. Legacy software becomes obsolete. Any one of these failures does not just mean a missing receipt; it means a breach of a mandatory retention requirement under Regulation 31A that could trigger a serious regulatory finding years, or even decades, down the line.

Without a dedicated, compliant digital archive, the question is not if records will be lost. It is when. Legacy BACS processes, which often rely on institutional finance records that are purged after seven years, are fundamentally incompatible with this new 25-year mandate.

3. Why spreadsheets and email breach Security & GDPR:

Q: Why is using Excel for clinical trial participant payments a GDPR risk?

A: Spreadsheets lack the immutable audit logs and granular access controls required for sensitive data. In the context of 2026 regulations, manual trackers are considered "Shadow IT," creating a significant security vulnerability and a high risk of a notifiable data breach under UK GDPR.

3.1 "DIY" Data Handling

Managing participant bank details and expense receipts is not routine administration. It is the handling of sensitive personal data governed by strict UK GDPR obligations. Relying on manual forms, which are often filled out by hand at the trial location or emailed, and sharing those details across the organisation creates what regulators call Shadow IT: data that exists outside official, secure IT systems.

Both the ICO and MHRA treat these manual workarounds as a serious security vulnerability. When personal financial information is moved through unencrypted email chains or stored in local spreadsheets, the organisation loses control of the data lifecycle. This directly impacts clinical trial participant reimbursement compliance and increases the risk of a notifiable data breach that may require mandatory reporting.

3.2 Spreadsheet Vulnerabilities

Excel is a powerful tool, but it was never designed to be a secure vault for sensitive participant data. It lacks the granular access controls and immutable audit logs that regulators require. Two risks stand out:

Leaving Colleague Problem: When a staff member manages trial expenses on a local drive or personal cloud account and then leaves the organisation, that data frequently leaves with them^[4]. This is a direct violation of the requirement for records to remain available and accessible for 25 years.

Shadow AI Threat: An emerging and underappreciated risk is the accidental use of public AI tools. If a team member pastes participant data into a public chatbot to clean up a list or reformat a file, that information is no longer private. Under UK GDPR, this constitutes a data breach regardless of intent.

3.3 Email as a Breach Vector

Email remains the most common channel through which sensitive data is leaked in the UK^[5]. For clinical trials, the consequences can be severe:

• The Wrong Recipient: A single auto-fill error can send a participant's bank details alongside their health-related trial involvement to the wrong person. This isn't just a mistake. It is a notifiable breach that may require mandatory reporting to the ICO
• The Hacker's Treasure Trove: Years of unencrypted sent items sit quietly in staff inboxes, containing participant financial and personal data. A single network compromise hands cybercriminals a ready-made library of sensitive information, exposing the organisation to significant fines and lasting reputational damage.

4. What MHRA Inspectors Actually Find

Q: What are common MHRA findings regarding clinical trial spreadsheets and data integrity?

A: Inspectors frequently cite "Shadow Trial Master Files^[6]" (Shadow TMFs) as a major deficiency. This refers to essential documents, such as participant reimbursement records, being stored in unmanaged folders or spreadsheets outside the primary electronic system, leading to fragmented audit trails and critical findings.

The MHRA's GCP Inspection Metrics reports make uncomfortable reading for anyone still running participant payments through spreadsheets and email. These annual summaries highlight recurring systemic failures in how data is archived and managed across the UK clinical research landscape.

Inspectors regularly identify "shadow Trial Master Files": unmanaged folders on shared drives used alongside an official paper record. When auditors review these shadow systems, essential documents are routinely missing. This alone can escalate an inspection to a Critical finding because it demonstrates a lack of oversight and a failure to maintain a complete, contemporaneous record of the trial.

Perhaps most damaging: if a sponsor cannot accurately document that a participant was reimbursed for the visit at which an adverse event occurred, the entire chronology of the trial is called into question. Under the 2026 framework, financial records are not an administrative afterthought. To an inspector, they are evidence. Failure to prove that a participant was paid accurately and on time can suggest a broader failure in trial conduct, jeopardising the integrity of the entire dataset.

5. What Good Looks Like: Moving Beyond BACS

Q: How can clinical trial sponsors ensure participant payments are GCP compliant?

A: Sponsors should implement a validated, digital-first payment platform that provides a complete, exportable audit trail. This allows financial data and metadata to be securely linked to the Trial Master File, ensuring reimbursements are contemporaneous, attributable, and archived to 2026 MHRA and ICH E6(R3) standards

The solution isn't complicated. It requires moving away from fragmented, manual processes toward a single, automated, digital-first payment framework. Here's what that looks like in practice:

Ditch the spreadsheets Validated payment platforms eliminate shadow Excel trackers and capture every transaction in an immutable audit trail. This moves your data from vulnerable local files into a secure, central system.

Pay participants immediately Digital reimbursement via instant bank transfers removes the out-of-pocket burden entirely. Because payments are tied to the actual visit in real time, they satisfy the contemporaneous requirement.

Archive from day one The 25-year retention mandate cannot be an afterthought. Using a validated system ensures that financial records and their associated metadata are preserved from the moment of payment, meeting the long term requirements of Regulation 31A.

Get email out of the loop Participant bank details should never travel via email or be stored on manual forms. Encrypted digital portals keep sensitive data secure and ensure full UK GDPR compliance

Stay inspection-ready MHRA inspectors expect to reconstruct a trial entirely from its records. A validated electronic system provides auditors with an unbroken chain of evidence, significantly reducing the risk of critical findings during an audit.

6. Conclusion: Transition to Digital-First Reimbursement

Q: What is the impact of the 2026 UK Clinical Trial Regulations on participant reimbursement for organisations using BACS?

 

A: BACS is a manual process that creates significant compliance gaps under the 2026 framework. To maintain trial integrity, sponsors must move toward digital tools that ensure participant payments are handled in a speedy, contemporaneous, and attributable manner.

Participant reimbursement is no longer a back‑office task. Under the 2026 framework, it sits at the heart of trial integrity, with financial records treated as critical evidence for reconstructing the trial chronology. Relying on manual, spreadsheet‑driven BACS processes creates a dangerous disconnect between clinical events and payments that will not survive modern MHRA inspection.

While BACS will remain a payment rail, the way it is used must change. Organisations that move to automated, digital‑first reimbursement systems eliminate high‑stakes compliance gaps, protect data for the full 25‑year retention period, and keep payments contemporaneous and attributable. Solutions like vHelp help sponsors and sites step away from ad‑hoc BACS workflows toward faster (typically within 24 hours), auditable participant payments that align with emerging MHRA expectations.

References

^[1] Pharmavibes (2025). New clinical trials legislation laid in UK parliament.

^[2] GOV.UK (2025). Archiving and retention of clinical trial records.

^[3] Regulation 31A, Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025

^[4] Palo Alto Networks. What Is Shadow Data? (Risk of unmanaged data silos)

^[5] ICO (Information Commissioner's Office). Personal data breach examples and reporting.

^[6] MHRA GCP Inspections Metrics Report (2018-2019)